Lyra Therapeutics' ENLIGHTEN 1 Trial Fails, Stock Plummets 93%; EyePoint's DURAVYU Trial Misses Endpoint

Lyra Therapeutics ($LYRA) faced setbacks as its ENLIGHTEN 1 trial did not meet the primary endpoint, leading to a 93% drop in stock value. EyePoint Pharmaceuticals ($EYPT) also experienced a decline after its Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy failed to meet the primary endpoint. Despite initial optimism with big funds and insider buying, $LYRA ultimately disappointed investors, highlighting the volatile nature of the biotech industry.